| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
- |
0.06 |
? － ? |
BC-3205  |
602 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
- |
0.12 |
? － ? |
Clindamycin (Cleocin) |
602 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
≤- |
≤0.25 |
≤0.25 － ? |
Clindamycin (Cleocin) |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
≤- |
≤0.5 |
≤0.5 － 2 |
Imipenem |
110 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
- |
0.5 |
? － ? |
Levofloxacin (Levaquin, Quixin) |
602 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
- |
2 |
? － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
602 |
| Staphylococcus aureus (community-acquired + methicillin-resistant) |
>- |
>16 |
? － ? |
Azithromycin (Zithromax, Sumamed, Zitrocin) |
602 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
0.12 |
0.25 |
0.06 － 1 |
Daptomycin (Cubicin) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
0.12 |
8 |
≤0.12 － >8 |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
0.25 |
0.5 |
0.12 － 0.5 |
Tigecycline (GAR-936, Tigacyl) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
1 |
1 |
≤0.25 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
2 |
2 |
≤0.12 － 4 |
Linezolid (PNU-100766, U-100766, Zyvox) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
>8 |
>8 |
≤0.25 － >8 |
Clindamycin (Cleocin) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
>8 |
>16 |
≤0.06 － >16 |
Moxifloxacin (BAY 12-8039, Avelox) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
>16 |
>16 |
0.25 － >16 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
>16 |
>16 |
≤0.25 － >16 |
Clarithromycin (Biaxin) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
>32 |
>32 |
0.12 － >32 |
Levofloxacin (Levaquin, Quixin) |
1376 |
| Staphylococcus aureus (community-associated + methicillin-resistant) |
>128 |
>128 |
1 － >128 |
Cefazolin (Ancef, Kefzol, Zolicef) |
1376 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
0.12 |
0.12 |
0.06 － 0.12 |
Solithromycin (CEM-101 and OP-1068) |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
≤0.12 |
≤0.12 |
≤0.12 － ? |
Clindamycin (Cleocin) |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
0.25 |
0.25 |
0.12 － 0.5 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
0.25 |
0.25 |
≤0.12 － 4 |
Levofloxacin (Levaquin, Quixin) |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
≤0.25 |
≤0.25 |
≤0.25 － 0.5 |
Trimethoprim/Sulfamethoxazole |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
0.5 |
0.5 |
0.5 － ? |
Quinupristin/Dalfopristin (Synercid) |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
2 |
2 |
1 － 2 |
Linezolid (PNU-100766, U-100766, Zyvox) |
1130 |
| Staphylococcus aureus (community-associated + meticillin-resistant) |
>4 |
>4 |
>4 － ? |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
1130 |
| Staphylococcus aureus (community-associated) |
0.008 |
0.008 |
0.004 － 0.015 |
API-1252 |
169 |
| Staphylococcus aureus (constitutively erm(A) + constitutively erm(C)) |
>128 |
>128 |
0.008 － >128 |
Cethromycin (ABT-773) |
954 |